INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Elanco Animal Health, Inc. (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9 a.m. to 12 p.m. Eastern Time in New York City. The event will feature presentations from Elanco's senior leadership team on the company's strategic priorities, financial outlook, and innovation pipeline – defining Elanco's new era of growth.
Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact This email address is being protected from spambots. You need JavaScript enabled to view it.. Registration and access for the live webcast and related materials will be available on Elanco's Investor Events and Presentations website. A replay will be available on the website following the event.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society, and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$21.75 |
| Daily Change: | 0.46 2.16 |
| Daily Volume: | 2,718,459 |
| Market Cap: | US$10.810B |
November 21, 2025 November 13, 2025 November 05, 2025 October 24, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load